Cargando…
Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes
Steady-state lymphatic endothelial cells (LECs) can induce peripheral tolerance by presenting endogenous antigens on MHC class I (MHC-I) molecules. Recent evidence suggests that lymph node LECs can cross-present tumor antigens on MHC-I to suppress tumor-specific CD8+ T cells. Whether LECs can act as...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654328/ https://www.ncbi.nlm.nih.gov/pubmed/36362253 http://dx.doi.org/10.3390/ijms232113470 |
_version_ | 1784828903396737024 |
---|---|
author | Li, Claire Y. Park, Hyeung Ju Shin, Jinyeon Baik, Jung Eun Mehrara, Babak J. Kataru, Raghu P. |
author_facet | Li, Claire Y. Park, Hyeung Ju Shin, Jinyeon Baik, Jung Eun Mehrara, Babak J. Kataru, Raghu P. |
author_sort | Li, Claire Y. |
collection | PubMed |
description | Steady-state lymphatic endothelial cells (LECs) can induce peripheral tolerance by presenting endogenous antigens on MHC class I (MHC-I) molecules. Recent evidence suggests that lymph node LECs can cross-present tumor antigens on MHC-I to suppress tumor-specific CD8+ T cells. Whether LECs can act as immunosuppressive cells in an MHC-II dependent manner in the local tumor microenvironment (TME) is not well characterized. Using murine heterotopic and spontaneous tumor models, we show that LECs in the TME increase MHC-II expression in the context of increased co-inhibitory signals. We provide evidence that tumor lymphatics in human melanoma and breast cancer also upregulate MHC-II compared to normal tissue lymphatics. In transgenic mice that lack LEC-specific MHC-II expression, heterotopic tumor growth is attenuated, which is associated with increased numbers of tumor-specific CD8+ and effector CD4+ T cells, as well as decreased numbers of T regulatory CD4+ cells in the TME. Mechanistically, we show that murine and human dermal LECs can take up tumor antigens in vitro. Antigen-loaded LECs in vitro can induce antigen-specific proliferation of CD8+ T cells but not CD4+ T cells; however, these proliferated CD8+ T cells have reduced effector function in the presence of antigen-loaded LECs. Taken together, our study suggests LECs can act as immunosuppressive cells in the TME in an MHC-II dependent manner. Whether this is a result of direct tumor antigen presentation on MHC-II requires additional investigation. |
format | Online Article Text |
id | pubmed-9654328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96543282022-11-15 Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes Li, Claire Y. Park, Hyeung Ju Shin, Jinyeon Baik, Jung Eun Mehrara, Babak J. Kataru, Raghu P. Int J Mol Sci Article Steady-state lymphatic endothelial cells (LECs) can induce peripheral tolerance by presenting endogenous antigens on MHC class I (MHC-I) molecules. Recent evidence suggests that lymph node LECs can cross-present tumor antigens on MHC-I to suppress tumor-specific CD8+ T cells. Whether LECs can act as immunosuppressive cells in an MHC-II dependent manner in the local tumor microenvironment (TME) is not well characterized. Using murine heterotopic and spontaneous tumor models, we show that LECs in the TME increase MHC-II expression in the context of increased co-inhibitory signals. We provide evidence that tumor lymphatics in human melanoma and breast cancer also upregulate MHC-II compared to normal tissue lymphatics. In transgenic mice that lack LEC-specific MHC-II expression, heterotopic tumor growth is attenuated, which is associated with increased numbers of tumor-specific CD8+ and effector CD4+ T cells, as well as decreased numbers of T regulatory CD4+ cells in the TME. Mechanistically, we show that murine and human dermal LECs can take up tumor antigens in vitro. Antigen-loaded LECs in vitro can induce antigen-specific proliferation of CD8+ T cells but not CD4+ T cells; however, these proliferated CD8+ T cells have reduced effector function in the presence of antigen-loaded LECs. Taken together, our study suggests LECs can act as immunosuppressive cells in the TME in an MHC-II dependent manner. Whether this is a result of direct tumor antigen presentation on MHC-II requires additional investigation. MDPI 2022-11-03 /pmc/articles/PMC9654328/ /pubmed/36362253 http://dx.doi.org/10.3390/ijms232113470 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Claire Y. Park, Hyeung Ju Shin, Jinyeon Baik, Jung Eun Mehrara, Babak J. Kataru, Raghu P. Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title | Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title_full | Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title_fullStr | Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title_full_unstemmed | Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title_short | Tumor-Associated Lymphatics Upregulate MHC-II to Suppress Tumor-Infiltrating Lymphocytes |
title_sort | tumor-associated lymphatics upregulate mhc-ii to suppress tumor-infiltrating lymphocytes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654328/ https://www.ncbi.nlm.nih.gov/pubmed/36362253 http://dx.doi.org/10.3390/ijms232113470 |
work_keys_str_mv | AT liclairey tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes AT parkhyeungju tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes AT shinjinyeon tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes AT baikjungeun tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes AT mehrarababakj tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes AT kataruraghup tumorassociatedlymphaticsupregulatemhciitosuppresstumorinfiltratinglymphocytes |